Akari Therapeutics (NASDAQ: AKTX) — Perfil da empresa, notícias e dados financeiros
Akari Therapeutics is a biopharmaceutical company innovating treatments for autoimmune diseases, focusing on nomacopan's clinical trials.
Akari Therapeutics
Akari Therapeutics (NASDAQ:AKTX) is a biopharmaceutical company engaged in the development of treatments for various autoimmune and inflammatory diseases. The company focuses on leveraging its innovative drug development platform to create therapies that address critical unmet medical needs, particularly in areas where inflammation plays a key role in disease progression. Akari's lead product candidate, nomacopan, is in various stages of clinical trials targeting conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atopic keratoconjunctivitis, and bullous pemphigoid. Akari's objectives are to advance the clinical development of its pipeline products, secure regulatory approvals, and ultimately improve patient outcomes in diseases with significant inflammatory components.
Resumo
Operações
Produtos e/ou serviços de Akari Therapeutics
- Nomacopan (Coversin), a complement C5 inhibitor aimed at treating paroxysmal nocturnal hemoglobinuria and other complement-driven diseases.
- A Phase III clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), addressing a significant unmet medical need in stem cell transplant recipients.
- Development of PAS-nomacopan, a long-acting version of nomacopan, designed to enhance patient compliance and extend the duration of therapeutic effects.
- Research into treating Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD) with nomacopan, exploring the role of complement in chronic diseases of the eye.
- Investigation into the efficacy of nomacopan for treating Bullous Pemphigoid (BP), a rare, chronic autoimmune skin disorder.
- A study on the use of nomacopan in treating atopic keratoconjunctivitis (AKC), offering potential relief for patients with severe eye allergies.
equipe executiva do Akari Therapeutics
- Abizer GaslightwalaCEO, President & Director
- Kameel D. FaragInterim Chief Financial Officer
- Satyajit MitraExecutive Director & Head of Oncology
Principais indicadores financeiros
Resultados divulgados pela Akari Therapeutics , em USD.
- Cap. de mercado
- 19,6 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -17,3 mi | -17,3 mi | |
| 0 | -21,6 mi | -19,8 mi | |
| 0 | -16,8 mi | -10 mi | |
| 0 | -23,1 mi | -17,7 mi |